Merrill moves Martek to neutral

Martek Biosciences Corp. was moved to a neutral rating from a sell by Merrill Lynch analyst David Munno on news that the company is considering potential food deals with several large companies and up to five food deals or product launches in 2006. Merrill believes the current price better reflects the intrinsic value of the core infant formula business and a risk-adjusted value for the food business. Shares of the Columbia, Md., pharmaceutical company were up $4.52, or 18.62%, at $28.80 on volume of 3,099,761 shares versus the three-month running average of 889,530 shares. (Nasdaq: MATK)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.